DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on October 22, 2007; DOI: 10.1124/dmd.107.017418


0090-9556/08/3601-137-145$20.00
DMD 36:137-145, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.017418v1
36/1/137    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanebratt, K. P.
Right arrow Articles by Andersson, T. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanebratt, K. P.
Right arrow Articles by Andersson, T. B.

HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans

Kajsa P. Kanebratt, and Tommy B. Andersson

Development DMPK & Bioanalysis, AstraZeneca R&D, Mölndal, Sweden (K.P.K., T.B.A.); Division of Clinical Pharmacology, Department of Laboratory Medicine at Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden (K.P.K.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (T.B.A.)

HepaRG is a highly differentiated cell line that displays several hepatocyte-like functions, including drug-metabolizing enzymes. In this study, the HepaRG cells were characterized and evaluated as an in vitro model to predict cytochrome P450 (P450) enzyme induction of drugs in humans. Exposure of HepaRG cells to prototypical inducers resulted in induction of CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 mRNA, as well as phenacetin O-dealkylase, bupropion hydroxylase, diclofenac 4'-hydroxylase, and midazolam 1'-hydroxylase activities. The observed induction is consistent with the previously reported expression of the nuclear receptors pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor, which are necessary for a P450 induction response. To avoid problems with toxicity and solubility, the induction potency of test compounds was evaluated by calculating the concentrations leading to a 2-fold increase of baseline mRNA or enzyme activity levels (F2 values) instead of EC50 values from full dose-response curves. For CYP3A4 mRNA, the obtained F2 values were related to the in vivo exposure [area under the plasma concentration versus time curve (AUC)] of the inducer (AUC/F2). This score was then correlated with the decrease in AUC for a CYP3A probe drug, administered before and after treatment with the inducing agent. By using this method an excellent correlation (R2 = 0.863) was obtained, which implies that the degree of CYP3A induction in vivo can be predicted from CYP3A4 mRNA induction in HepaRG cells. The present study shows that HepaRG cells are a valuable model to be used for prediction of induction of drug-metabolizing P450 enzymes in vivo in humans.


Address correspondence to: Tommy B. Andersson, Development DMPK & Bioanalysis, AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden. E-mail: tommy.b.andersson{at}astrazeneca.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
V. Chu, H. J. Einolf, R. Evers, G. Kumar, D. Moore, S. Ripp, J. Silva, V. Sinha, M. Sinz, and A. Skerjanec
In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective
Drug Metab. Dispos., July 1, 2009; 37(7): 1339 - 1354.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. F. McGinnity, G. Zhang, J. R. Kenny, G. A. Hamilton, S. Otmani, K. R. Stams, S. Haney, P. Brassil, D. M. Stresser, and R. J. Riley
Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells
Drug Metab. Dispos., June 1, 2009; 37(6): 1259 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
O. A. Fahmi, S. Boldt, M. Kish, R. S. Obach, and L. M. Tremaine
PREDICTION OF DRUG-DRUG INTERACTIONS FROM IN VITRO INDUCTION DATA: Application of the Relative Induction Score Approach Using Cryopreserved Human Hepatocytes
Drug Metab. Dispos., September 1, 2008; 36(9): 1971 - 1974.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. P. Kanebratt and T. B. Andersson
Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies
Drug Metab. Dispos., July 1, 2008; 36(7): 1444 - 1452.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Gupta, G. M. Mugundu, P. B. Desai, K. E. Thummel, and J. D. Unadkat
Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors
Drug Metab. Dispos., June 1, 2008; 36(6): 1172 - 1180.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.